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The progressive conversion of normal cells into cancer cells is characterized by the acqui-
sition of eight hallmarks. Among these criteria, the capability of the cancer cell to avoid
the immune destruction has been noted. Thus, tumors develop mechanisms to become
invisible to the immune system, such as the induction of immunosuppressive cells, which
are able to inhibit the development of an efficient immune response. Molecules produced
in the tumor microenvironment are involved in the occurrence of an immunosuppressive
microenvironment. Recently, it has been shown that vascular endothelial growth factor A
(VEGF-A) exhibits immunosuppressive properties in addition to its pro-angiogenic activities.
VEGF-A can induce the accumulation of immature dendritic cells, myeloid-derived suppres-
sor cells, regulatory T cells, and inhibit the migration of T lymphocytes to the tumor. Other
pro-angiogenic factors such as placental growth factor (PlGF) could also participate in tumor-
induced immunosuppression, but only few works have been performed on this point. Here,
we review the impact of pro-angiogenic factors (especially VEGF-A) on immune cells. Anti-
angiogenic molecules, which target VEGF-A/VEGFR axis, have been developed in the last
decades and are commonly used to treat cancer patients.These drugs have anti-angiogenic
properties but can also counteract the tumor-induced immunosuppression. Based on these
immunomodulatory properties, anti-angiogenic molecules could be efficiently associated
with immunotherapeutic strategies in preclinical models.These combinations are currently
under investigation in cancer patients.
Keywords: pro-angiogenic factors, VEGF-A, PlGF, tumor, immunosuppression, regulatory T cells, MDSC,
immunotherapy
INTRODUCTION
Tumorigenesis is a multistep process in which a succession of
genetic alterations, conferring some proliferative advantages, leads
to the progressive conversion of normal cells into cancer cells.
In 2000, Hanahan and Weinberg have grouped these genetic
alterations into six distinctive and complementary biologic capa-
bilities that constitute the six hallmarks criteria of cancer (1).
They include sustaining proliferative signaling, evading growth
suppressors, resisting cell death, enabling replicative immortal-
ity, activating invasion and metastasis, and inducing angiogenesis.
Although these hallmarks criteria are mainly due to the accumu-
lation of cell-intrinsic modifications, emerging evidences suggest
that “tumor microenvironment,” i.e., cells infiltrating the tumors
and molecules produced inside, contributes also to the biology
of many cancers. In the light of this new concept, Hanahan and
Weinberg have revisited their criteria in 2011 and added two
emerging criteria: deregulating cellular energetics and avoiding
immune destruction (2).
The concept that the immune system can recognize and destroy
cancer cells and so repress the development of tumor has first
been described in 1909 by Paul Erhlich and then rephrased in
1957 by Sir MacFarlane Burnet and Lewis Thomas in the cancer
immunosurveillance hypothesis (3–5). Nevertheless, this hypoth-
esis was definitively accepted recently with studies highlighting
the role of the immune system in controlling cancer development
in animal models and in immunodeficient or immunosuppressed
patients. Thus, Shankaran et al. have demonstrated that mice defi-
cient for T and B lymphocytes (RAG2−/− mice) or mice deficient
for interferon gamma signaling develop more frequently sponta-
neous cancer and carcinogen-induced cancer than wild type mice
(6). In humans, immunodeficient or immunosuppressed patients
had a higher incidence of cancer of non-viral origin (colon, lung,
pancreas, melanoma) than immunocompetent patients (7–10).
In addition, some immunosuppressed transplant recipients have
been observed to develop tumor derived from the donor organ,
underlining the importance of the immune system as an effective
barrier to the tumor progression (11, 12). Finally, recent works
have demonstrated that tumor infiltration by different immune
cells (NK or T cells) was correlated with good prognosis in var-
ious cancers (13). For example, in colorectal cancer, Pagès and
Galon have demonstrated that the absence of pathological signs
of early metastatic invasion (vascular emboli, lymphatic inva-
sion, and perineural invasion) was correlated with the presence
of effector memory T cells (CD45RO+) within the tumor and
a better overall and disease-free survival (14). The density of T
cells (CD3+) infiltrating the tumor was also correlated with the
outcome and seems to have a better and independent prognostic
value for overall survival than the usual histopathologic prognostic
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factor (UICC-TNM classification) (15). Thus, to become clini-
cally detectable in the immunocompetent host, cancer cells have
to bypass this immunosurveillance by downregulating expression
of molecules that are involved in immune recognition or by engen-
dering a state of immunosuppression linked to the recruitment of
immunoregulatory cells within the tumor or the production of
immunosuppressive factors.
Recently, accumulative evidence suggests that pro-angiogenic
factors could induce tumor growth and metastasis, not only by
promoting angiogenesis but also by favoring this immunosup-
pressive microenvironment.
A better knowledge of this link between angiogenesis
and immune escape could lead investigators to devise new
therapeutic strategies combining anti-angiogenic therapy and
immunotherapy.
PRO-ANGIOGENIC FACTORS PROMOTE INTRATUMORAL
IMMUNOSUPPRESSIVE MICROENVIRONMENT
Angiogenesis,which is defined by the sprouting of new vessels from
pre-existing ones, is a dynamic process that is observed under phys-
iological conditions (embryogenesis and wound healing) but also
under pathological conditions as tumor progression. In contrast
with physiological angiogenesis that is transiently activated, patho-
logical angiogenesis is almost always activated and remains on,
resulting from a permanent imbalance between pro-angiogenic
and anti-angiogenic factors. The absence of oxygen in the center
of the tumor induces a hypoxic stress, which plays a key role in
the regulation of angiogenesis. Hypoxia induces the stabilization
and nuclear accumulation of the hypoxia-inducible factor (HIF),
transcriptional factors, which results in the production of many
pro-angiogenic factors including vascular endothelial growth fac-
tor A (VEGF-A) (16). VEGF-A plays a central role in inducing
tumor angiogenesis. VEGF-A is a glycoprotein (45 kDa) that is
produced by nearly all tumor cells (17) and is found at elevated
levels in the serum of cancer patients (18). It binds to two key
receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1, KDR), and one
co-receptor (Neuropilin-1) to exert its pro-angiogenic activities.
Although VEGF-A was initially identified as an endothelial cell-
specific growth factor, it has become increasingly apparent that
the functions of VEGF-A were more extensive, and especially act
on immunity. Other pro-angiogenic factors like placental growth
factor (PlGF) can also modulate intratumoral immunosuppres-
sive microenvironment. PlGF is a member of the VEGF family,
which is produced by tumor cells and stromal cells. It binds to
VEGFR1 and induces migration and maturation of blood vessels
by favoring proliferation, migration, and survival of endothelial
cells. PlGF is correlated to tumor stage, to metastatic invasion,
and inversely to survival in different solid tumors (19). PlGF
also exhibits immunomodulatory properties (20). VEGF recep-
tors can be expressed on endothelial cells, tumor cells, and some
immune cells (21–23). VEGFR1 binds VEGF-A with higher affin-
ity than VEGFR2 does, but VEGFR1 has a poor tyrosine kinase
activity. Signaling pathways involved in VEGFR1 are confused.
VEGFR1 may form heterodimers with VEGFR2 on endothelial
cells as a consequence of VEGF-A binding and may also func-
tion as a decoy receptor sequestering VEGF-A from VEGFR2.
But VEGFR1 may also transduce signals resulting in activation of
proliferation, migration of the cells by activating Erk/MAPkinases,
PI3K/Akt, PLCγ, and p38/MAPkinases (Figure 1) (24). VEGFR2
activation induces many biological responses such as proliferation,
migration, survival by activation of PLCγ, Raf-kinases, and PI3K
pathways (Figure 1).
VEGF AND PLGF INHIBIT DENDRITIC CELL MATURATION
Mature DCs are critical elements of anti-tumor immunity since
professional antigen-presenting cells (APC) are responsible for the
presentation of tumor-specific antigens and the triggering of an
adaptive immune response mediated by T-cells (25). Conversely,
in tumor-bearing mice (26) and cancer patients, differentiation
and maturation of DC are impaired. Thus, immature DCs are
not able to efficiently present tumor antigens to naive T-cells and
therefore promote immune tolerance. The increase of the propor-
tion of immature DC in the peripheral blood is correlated with
the stage of the disease in cancer patients and is partially cor-
rected by surgery, suggesting that this phenomenon is linked to
a tumor-derived factor (27). The proportion of immature DC in
the blood of cancer patients is closely associated with an increased
VEGF-A plasma level. In mouse models, different studies have
shown that VEGF-A binding to VEGFR1 blocks the activation of
the transcriptional factor NF-κB (nuclear factor-κB) and leads to
inhibit DC maturation (28, 29). According with these results, PlGF,
which binds specifically to VEGFR1, can also modulate DC differ-
entiation, through the same mechanism (20, 30). In an in vitro
model of dendritic cell differentiation from embryonic stem cells
exposed to VEGF-A, Dikov et al. showed that VEGFR1 is involved
in the inhibition of the final maturation of DC and VEGFR2
affects the differentiation of DC from early hematopoietic prog-
enitors (20). Another in vitro study has shown that VEGF-A can
alter the differentiation of monocytes into DC, effect reversed
by anti-VEGF-A (bevacizumab) or sorafenib, an anti-angiogenic
molecule targeting different receptors (VEGFR, PDGFR, and Raf-
kinases) (31). Administration of exogenous VEGF-A to tumor-free
mice using osmotic pumps to mimic the VEGF concentrations
observed in advanced cancer patients also blocks the ability of
DC to stimulate allogeneic T-cell proliferation (32). Altogether,
these results provide strong evidence that pro-angiogenic factor
can inhibit DC maturation through both VEGFR1 and VEGFR2
pathways.
PRO-ANGIOGENIC FACTORS FAVOR THE ACCUMULATION OF
IMMUNOREGULATORY CELLS (MDSC, Treg, TUMOR-ASSOCIATED
MACROPHAGES, Tie-2+ MONOCYTES)
Myeloid-derived suppressor cells (MDSC) are a heterogeneous
group of cells of myeloid origin, including myeloid progenitor
cells and immature myeloid cells (macrophages, granulocytes, and
dendritic cells) with immunosuppressive properties. MDSC accu-
mulation in the tumor microenvironment leads to suppress T-cell
response in different ways. MDSCs can first metabolize l-Arginine,
an essential amino-acid for adult mammals that is required for T-
cell proliferation (33, 34): (i) using Arginase1, which results in a
reduction of extra-cellular levels of l-Arginine (35); (ii) using the
iNOS enzyme, which results in the generation of NO. The accumu-
lation of NO in the tumor microenvironment blocks the prolifer-
ation of T cells and induces their apoptosis resulting in a decrease
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FIGURE 1 |VEGFR signaling pathways.
of tumor-infiltrating T-cells (36, 37). MDSCs can also exert their
immunosuppressive properties by producing indoleamine 2,3-
dioxygenase, reactive oxygen species (ROS), like radical superox-
ide (O2•−) (38). Finally, reactivity between radical superoxide
(O2•−) and NO, both produced by MDSC, leads to the formation
of free radical peroxynitrite in the tumoral microenvironment that
blocks the ability of T cells to recognize specific peptide/MHC
complexes and perform their anti-tumor activity. MDSC can also
control NK cell activation through membrane-bound TGFβ and
NKp30 in an orthotopic mouse model of liver cancer and in hepa-
tocellular carcinoma-bearing mice, respectively (39, 40). VEGF-A
can promote the accumulation of MDSC (41). Indeed, Almand
et al. reported an increase of MDSC in cancer patients, that is,
associated with a decrease of mature DC. This accumulation is cor-
related with the disease stage and serum VEGF-A levels (27, 42).
Moreover, an increase of Gr1+CD11b+ cells (MDSC) in the spleen
of tumor-free mice treated with VEGF-A compared with control
mice has been observed, and this effect is mediated by VEGFR2
(32) and activation of JAK2 (JAnus Kinase 2) and the transcription
factor STAT3 (signal transducer and activator of transcription 3)
downstream (43).
Pro-angiogenic factors could also contribute to other immuno-
suppressive cell accumulation such as regulatory T cell (Treg)
in tumor-bearing hosts through direct or indirect mechanisms.
Thus, MDSC, which are enhanced by VEGF, could induce de novo
development of other immunosuppressive cells as of Foxp3+ Tregs
through a TGF-β-dependent (44, 45) and/or independent pathway
(46). Thus, in a mouse model of colon carcinoma, Gr1+CD115+
MDSC were shown to mediate the development of Treg by pro-
ducing IL-10 and TGF-β (44). Immature DC can also induce
Treg differentiation and proliferation in a TGFβ-dependent man-
ner (47). Moreover, we have recently shown that VEGF-A, could
also directly induce Treg proliferation in tumor-bearing mice
and metastatic colorectal patients in a VEGFR2-dependent man-
ner (22). Analysis of VEGFR expression on Tregs shows that
Tregs express VEGFR2 only in tumor-bearing hosts but not in
tumor-free mice (22).
Tumor-associated macrophages (TAM), which are correlated
with poor prognosis (48–51), are induced by VEGF-A. But its
development also needs the action of other cytokines produced by
the tumor such as IL-10 and IL-4 (52). Another pro-angiogenic
factor, angiopoietin-2 has also an impact on immune cells.
www.frontiersin.org April 2014 | Volume 4 | Article 70 | 3
Voron et al. Control of the immune response by pro-angiogenic factors
FIGURE 2 | Pro-angiogenic factors induce the development of an immunosuppressive state in tumors. VEGF-A induces the accumulation of MDSC,
immature DC, Treg, and tumor-associated macrophages (TAM). MDSC and Treg are able to control activation of T cells and NK cells.
Angiopoietin-2 induces the release of IL-10 by Tie-2-expressing
monocytes. Expression of angiopoietin-2 by tumor cells induces
the recruitment of Tie-2-expressing monocytes in the tumor and
the release of IL-10 by the cells (53, 54). IL-10 production by Tie-2-
expressing monocytes suppresses T-cell proliferation, increases the
ratio of CD4+ T cells to CD8+ T cells, and promotes the expansion
of CD4+CD25hiFOXP3+ Tregs (53).
In conclusion, pro-angiogenic factors could contribute to the
accumulation of immunosuppressive cells (MDSC, Treg, TAM,
and Tie-2-expressing monocytes) in tumor-bearing hosts through
direct or indirect mechanisms (Figure 2).
PRO-ANGIOGENIC FACTORS AND CONVENTIONAL T CELLS
Vascular endothelial growth factor A could inhibit the production
of T cells, which are the major immune effector cells, by inter-
fering with their development in thymus, as described by Ohm
et al. (55). In this study, administration of exogenous VEGF-A to
tumor-bearing mice at concentrations similar to those observed in
advanced stage cancer patients leads to profound thymic atrophy,
as observed in childhood malignancies, with a decrease in thymo-
cyte cellularity. This inhibition of thymocyte maturation is caused
through VEGFR2 pathway (32).
There are evidences for circulating T-cells in the periphery of
tumor-bearing mice (56, 57) and cancer patients (58, 59), which
are yet unable to control tumors (60). Thus, tumor angiogenesis,
driven by pro-angiogenic factors, leads to the formation of a new
vasculature that is structurally and functionally abnormal. New
vessels are dilated, tortuous, and saccular, with disorganized and
heterogeneous interconnections, resulting in hyperpermeable and
insufficient vessels that could contribute to impediment of T cells
extravasation. This hypothesis is reinforced with the recent work
of Hamzah et al. using a genetically modified model of spon-
taneous pancreatic islet carcinoma in which the inactivation of
Rgs5 (Regulator of G-protein signaling 5), a master gene con-
trolling the aberrant morphology of tumor vasculature in mice
and expressed by pericytes in the vascular bed, leads to nor-
malization of tumors vessels (61). In this model where Rgs5 is
inactivated, adoptive T-cell transfer results in massive infiltra-
tion of CD8+ and CD4+ lymphocytes within the tumor, whereas
wild type tumors showed no significant increase of intratu-
moral immune cells. In another model, overexpression of the
histidine-rich glycoprotein (HRG) induces tumor vessels nor-
malization through a down regulation of PlGF, and at the same
time, leads to an increase of CD8+ lymphocyte infiltration within
the tumor (62). Taken together, these results show a direct link
between tumor vasculature normalization and enhanced immune
cell infiltration.
Vascular endothelial growth factor A has also been shown
to decrease effector functions (proliferation and cytotoxicity) of
T lymphocytes obtained from peripheral blood and ascites of
ovarian cancer patients (63, 64).
On the other hand, exposure of tumor cells to hypoxia prevents
cytotoxic T lymphocyte (CTL)-mediated lysis of tumor cells (65).
This phenomenon depends on hypoxia-induced VEGF-A since
VEGF-A neutralization restores the susceptibility of tumor cells to
CTL lysis and also on STAT3 activation.
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Thus, VEGF-A can induce an immunosuppressive microenvi-
ronment by targeting immune cells but also tumor cells.
ANTI-ANGIOGENIC THERAPY CAN REVERSE
IMMUNOSUPPRESSION
Anti-angiogenic molecules have been developed to inhibit a major
hallmark of cancer: angiogenesis. These treatments target prefer-
entially the VEGF pathway since it has been revealed as a key reg-
ulator of angiogenesis, and include three types of VEGF-targeted
agents: neutralizing antibodies to VEGF or VEGF receptors (like
bevacizumab), tyrosine kinase inhibitors (TKI) that block intra-
cellular signaling pathway (like sunitinib that targets VEGFR1–3,
PDGFR, c-kit, and Flt3, or sorafenib that targets VEGFR1–3,
PDGFR, c-kit, and Raf-kinases), and inhibitors of the mTOR
pathway (like temsirolimus and everolimus) (Figure 1). The use
of this VEGF-targeted therapy has been approved for metastatic
colorectal cancer (66), hepatocellular carcinoma (67), clear-cell
renal carcinoma (68), breast cancer (69), and non-small-cell lung
carcinoma (70), alone or in combination with chemotherapy.
These treatments can impact multiple pathways, act on tumor and
endothelial cells, and block the neoangiogenesis. But they can also
modulate other cells especially cells expressing VEGFR. According
with the results presented above on the impact of pro-angiogenic
factors on immunity, recent data suggest that anti-angiogenic ther-
apy could reverse some immunosuppressive mechanisms involved
in tumor escape and tumor growth and lead to improve cancer
immunosurveillance.
VEGF-TARGETED THERAPY MODULATES NUMBER AND FUNCTIONS OF
IMMUNOSUPPRESSIVE CELLS
Gabrilovich et al. have shown that anti-VEGF antibody signifi-
cantly enhances the maturation of DC, resulting in an increase
of number and functions of lymph nodes and spleen DCs in
tumor-bearing mice treated with anti-VEGF-A (71). Osada has
then confirmed this result in humans by demonstrating an increase
in the number of DCs in peripheral blood and an improvement
of DCs functions in advanced solid cancer patients treated with
bevacizumab (anti-VEGF-A) (72). Blockade of VEGF-A pathway
by anti-VEGF-A antibody in tumor-bearing mice also leads to a
significant reduction of MDSCs in peripheral blood, as compared
with untreated mice (73). Similarly, a decrease in the absolute
number of MDSC in the spleen, bone marrow, and tumor in dif-
ferent tumor models (the MCA26 colorectal cancer, or the Renca
renal cancer), has also been observed after treatment with suni-
tinib (74, 75). Furthermore, this decrease was associated with a
reduction of immunosuppressive activity in vitro of MDSCs from
sunitinib-treated mice, compared with MDSC from PBS-treated
control mice (74). Inhibition of VEGF-A pathway could explain its
activity on MDSCs since anti-VEGF antibody decreases a CD11b+
VEGFR1+ subset of MDSC that is able to suppress T-cell response
(73) but Xin et al. have also demonstrated that sunitinib could
act on MDSCs by inhibiting Stat3 (75). Analysis of the impact of
sunitinib on MDSC reveals that it inhibits the proliferation of the
monocytic subset of MDSC (Gr1lo) and induces the apoptosis of
the granulocytic subset (Gr1hi) (75). Treatment with sorafenib in
a mouse model of liver tumor leads also to a decrease in MDSC
levels in the spleen and bone marrow (76). Since MDSC levels in
the peripheral blood of patients with head and neck cancer, non-
small-cell lung cancer, breast cancer are positively correlated with
plasma level of VEGF-A, VEGF-targeted therapy could induce a
decrease of MDSCs in peripheral blood of cancer patients (27). In
metastatic renal cell carcinoma patients, treatment with sunitinib
decreases the percentage of MDSCs in peripheral blood, after one
cycle of treatment (5.42% of PBMC before treatment vs. 2.28%
after one cycle; p= 0.007), but also after the second cycle (2.28 vs.
1.29%; p= 0.02) (77).
Vascular endothelial growth factor-targeted therapy can also
decrease Treg, either by inhibiting accumulation of MDSCs and
immature DC in tumor microenvironment or directly through
VEGF/VEGFR pathway inhibition on Treg. Thus, we have demon-
strated recently that treatment of CT26 colorectal tumor-bearing
mice with sunitinib or anti-VEGF-A antibody reduces the percent-
age and the absolute number of Treg in the spleen and tumor as
compared with non-treated tumor-bearing mice (22). In the same
manner, treatment with other anti-angiogenic therapies, such as
sunitinib and sorafenib, modulates accumulation of Treg in tumor
and spleen of various mouse tumor models (22, 76, 78, 79). Differ-
ent mechanisms of sunitinib action have been proposed: (i) Treg
decrease could be associated to the reduction of MDSC (77); (ii)
a blockade of conversion of conventional CD4+ Foxp3− T cells
into regulatory CD4+ Foxp3+ T cells (80); (iii) a reduction of the
proliferation of pre-existing Tregs (22). In cancer patients, anti-
angiogenic treatments also reduce Tregs in periphery. Sunitinib
treatment decreases the number of Foxp3+ Tregs in the peripheral
blood of metastatic renal cancer patients (79) and this decrease
was positively correlated with a better overall survival (81, 82).
Similarly, sorafenib treatment induces a reduction in regulatory
T-cell number in the peripheral blood of patients with hepatocel-
lular carcinoma (83). Bevacizumab, which is used in association
with chemotherapy as a first-line treatment in metastatic colorec-
tal cancer patients, also decreases regulatory T-cell proportion in
the peripheral blood of these patients. This decrease is linked to a
reduction of Treg proliferation (22).
ANTI-ANGIOGENIC MOLECULES AND CONVENTIONAL T CELLS
Ozao-Choy et al. have demonstrated in tumor-bearing mice that
sunitinib treatment enhances the percentage and number of
intratumoral CD4+ and CD8+ T-cells compared with tumor-
bearing mice treated with PBS (74). Similarly, blockade of VEGF-
A/VEGFR2 pathway in tumor-bearing mice improves the infiltra-
tion of adoptively transferred T cells into the tumor and tumor
regression (84). This better infiltration could be associated with
the capacity of anti-angiogenic molecules to normalize tumor vas-
culature and probably to prevent loss of ICAM-1 and VCAM-1
on endothelial cells (85). Sunitinib treatment can also modulate
expression of inhibitory molecules on tumor-infiltrating T cells
such as PD-1, CTLA-4 (74).
IMPACT OF STRATEGY COMBINING ANTI-ANGIOGENIC
THERAPY WITH IMMUNOTHERAPY
Anti-angiogenic drugs have improved the treatment of many
solid tumors. These molecules have anti-angiogenic impact
but also immunomodulatory properties (86, 87). As described
above, anti-angiogenic drugs inhibit the accumulation of
www.frontiersin.org April 2014 | Volume 4 | Article 70 | 5
Voron et al. Control of the immune response by pro-angiogenic factors
immunosuppressive cells (immature myeloid cells such as imma-
ture dendritic cells and MDSC, Treg), which are able to inhibit the
development of an efficient anti-tumor immune response. They
can also enhance the proportion of tumor-infiltrating T lympho-
cytes probably by normalizing tumor vessels and by modulating
the expression of adhesion molecules involved in T-lymphocyte
extravasation (88). Sunitinib can also enhance the Th1 response of
T lymphocytes derived from metastatic renal cancer patients after
mitogen restimulation (81). However, they do not seem able to
restore a spontaneous specific T-cell response to tumor antigens.
Based on their immunomodulatory properties, anti-angiogenic
drugs could be combined to immunotherapeutic strategies to
obtain durable anti-tumor responses. Recently, immunotherapy
has obtained successes, especially in the treatment of metastatic
solid cancer patients, where anti-CTLA-4 or anti-PD1 antibod-
ies administration results in an enhancement of the proportion of
objective and durable responses (89, 90). Furthermore, Sipuleucel-
T is the first vaccination strategy approved by the FDA for the
treatment of patient with castration-resistant prostate cancer.
This vaccine induces an improvement of overall survival (91).
The future of immunotherapy will probably involve combina-
tion with other immunomodulatory agents. Different groups tried
to combine immunotherapeutic strategies with anti-angiogenic
molecules in mouse tumor models. The most commonly used
molecule in these studies is sunitinib. Association of sunitinib with
adenoviral vectors encoding for IL-12 and other immunostimu-
lating molecules or pox-virus encoding for stimulatory molecules
and tumor antigen decreased tumor growth in different mouse
models (colorectal cancer, hepatocellular carcinoma) (74, 92).
To design relevant protocols of treatment with anti-angiogenic
molecules and immunotherapy, it is necessary to determine the
scheduling of drug administration. Administration of sunitinib
before vaccination induced a superior anti-tumor efficacy than
administration after vaccination or concurrently (92). A recent
work has even shown that sunitinib administration concurrently
with a vaccine against a tumor antigen results in a lack of reactiv-
ity against the tumor antigen in a mouse mammary tumor model.
The strategy failure seems to be due to a transient loss of CD11c+
CD11b+ APC in the lymph nodes, which inhibits the priming
of T lymphocytes (93). To optimize strategies combining anti-
angiogenic drugs to immunotherapy, we also need to determine
which anti-angiogenic should be used and at which dosage. VEGF-
A/VEGFR2 targeted therapies seem to be the best choice, since they
can modulate both Treg and MDSC. Administration of low-doses
of anti-VEGFR2 antibody results in a transient vascular normal-
ization and improves the CD4+ and CD8+ tumor infiltration.
Association of low-doses of anti-VEGFR2 with whole cancer cell
vaccine induces anti-tumor efficacy (94).
Interestingly in metastatic renal cancer, two patients received
sunitinib before radical nephrectomy and dendritic cell therapy.
These two patients displayed disease stabilization after sunitinib
treatment and regression of metastatic lesions after nephrectomy
and DC vaccine, suggesting that sunitinib could synergize with
DC vaccine (95). In an open-label phase II trial, 21 metastatic
renal cancer patients received sunitinib and a DC-based vaccine
(AGS-003). This vaccine consists of mature monocyte-derived
DC electroporated with mRNA harvested from the patient’s
tumor and synthetic CD40L mRNA. This combination resulted
in an interesting progression-free survival and overall survival.
An international phase 3 trial will be launched based on these
results (NCT01582672). Other clinical trials are testing combi-
nation between anti-angiogenic drugs and immunotherapy in
Table 1 | Ongoing clinical trials, according to National Cancer Institute (NCI) registration, using association of anti-angiogenic drugs with
immunotherapy.
Anti-angiogenic Immunotherapy Cancer Phase Status Registration
number
Bevacizumab MK-3475 (anti-PD1) Locally advanced or metastatic
non-small-cell lung carcinoma
I/II Recruiting NCT02039674
Bevacizumab MPDL3280A (anti-PDL1) Advanced solid tumors I Recruiting NCT01633970
Bevacizumab Ipilimumab (anti-CTLA4) Unresectable stage III or IV melanoma I Active, not recruiting NCT00790010
Bevacizumab Ipilimumab (Anti-CTLA4) Unresectable stage III or IV melanoma II Not yet recruiting NCT01950390
Bevacizumab Nivolumab (anti-PD1) Stage IIIB/IV non-small-cell lung cancer I Recruiting NCT01454102
Sunitinib Nivolumab (anti-PD1) Metastatic renal cell carcinoma I Active, not recruiting NCT01472081
Bevacizumab Dendritic cell immunotherapy Resected hepatic metastasis of colorectal
carcinoma
II Recruiting NCT01348256
Bevacizumab Vaccin TG4010 Stage IV non-small-cell lung cancer (TIME) II/III Recruiting NCT01383148
Bevacizumab Dendritic cell vaccination Newly diagnosed or recurrent
glioblastoma
I Recruiting NCT02010606
Sunitinib Autologous dendritic cell
immunotherapy (AGS-003)
Advanced renal cell carcinoma III Recruiting NCT01582672
Sorafenib Interleukin 21 Renal cell carcinoma I/II Completed (96) NCT00389285
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cancer patients, especially association of antibodies targeting
inhibitory immune checkpoints (anti-PD-1, anti-CTLA-4) with
bevacizumab or sunitinib (Table 1).
CONCLUSION
Pro-angiogenic factors and especially VEGF-A modulate the
tumor microenvironment. VEGF-A plays a key role in control-
ling tumor angiogenesis but also in modulating tumor-induced
immunosuppression (accumulation of immature DC, MDSC,
Treg). Anti-angiogenic drugs can decrease immunosuppression.
However, these molecules are not able to reactivate efficient
immune responses against the tumor. In this goal, association of
anti-angiogenic molecules to immunotherapeutic strategies could
be of major interest. Different preclinical models have shown
that this combination can induce potent anti-tumor response.
To optimize protocols of treatment with anti-angiogenic drugs
and immunotherapeutic strategies, different parameters should
be analyzed such as the scheduling of the treatment and the doses
of anti-angiogenic drugs to administer.
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